Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study

中止 医学 队列 内科学 髓系白血病 前瞻性队列研究 队列研究 肿瘤科
作者
Giovanni Paolo Maria Zambrotta,Franck Emmanuel Nicolini,Sarit E. Assouline,Lambert Busque,Ester Maria Pungolino,Elisabetta Abruzzese,Maria Cristina Miggiano,Chiara Elena,Alberto Álvarez‐Larrán,Ana Triguero,Alessandra Iurlo,Cristina Bucelli,Marco Cerrano,Isabella Capodanno,Francesca Lunghi,Philipp le Coutre,Sara Galimberti,Giovanni Caocci,Margherita Maffioli,Fabio Stagno
出处
期刊:American Journal of Hematology [Wiley]
卷期号:98 (11): 1762-1771 被引量:12
标识
DOI:10.1002/ajh.27073
摘要

Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP-CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD-eligible patients, we conducted TFR-PRO, a cohort retro-prospective study: 870 CP-CML patients eligible for TD formed a discontinuation cohort (505 patients) and a reference one (365 patients). The primary objective was the time adjusted rate (TAR) of progression in relation to TD. Secondary endpoints included the TAR of molecular relapse, that is, loss of major molecular response (MMR). With a median follow up of 5.5 years and 5188.2 person-years available, no events occurred in the TD cohort. One event of progression was registered 55 months after the end of TD, when the patient was contributing to the reference cohort. The TAR of progression was 0.019/100 person-years (95% CI [0.003-0.138]) in the overall group; 0.0 (95% CI [0-0.163]) in the discontinuation cohort; and 0.030 (95% CI [0.004-0.215]) in the reference cohort. These differences are not statistically significant. Molecular relapses occurred in 172/505 (34.1%) patients after TD, and in 64/365 (17.5%) patients in the reference cohort, p < .0001. Similar rates were observed in TD patients in first, second or third line of treatment. CML progression in patients eligible for TD is rare and not related to TD. Fears about the risk of disease progression among patients attempting TD should be dissipated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
彭于晏的应助被fengjingjing采纳,获得10
2秒前
2秒前
可爱的函函的应助被wwwww采纳,获得10
4秒前
Orange的应助被Omni采纳,获得10
4秒前
龙龙宝宝发布了新的文献求助10
4秒前
齐天大圣完成签到,获得积分10
5秒前
Hello的应助被天天采纳,获得10
6秒前
娃1完成签到,获得积分10
6秒前
楚轩之圣完成签到,获得积分10
7秒前
7秒前
FashionBoy的应助被hehe_733采纳,获得10
7秒前
Lesley完成签到,获得积分10
9秒前
9秒前
核桃发布了新的文献求助30
10秒前
爆米花的应助被Suzana采纳,获得10
10秒前
wwwww完成签到,获得积分10
10秒前
fantasy的应助被超级的海豚采纳,获得10
11秒前
Yaya发布了新的文献求助10
13秒前
琴歌茶赋完成签到,获得积分10
13秒前
15秒前
bkagyin的应助被lalaland采纳,获得10
15秒前
speansean完成签到,获得积分20
16秒前
稳妥完成签到,获得积分10
16秒前
17秒前
Yuanlang发布了新的文献求助10
18秒前
hehe_733完成签到,获得积分10
18秒前
19秒前
无我完成签到,获得积分10
19秒前
草莓夏冰雹完成签到,获得积分10
19秒前
英姑的应助被怕孤单的英姑采纳,获得10
20秒前
waka完成签到,获得积分20
20秒前
hehe_733发布了新的文献求助10
21秒前
隔岸完成签到 ,获得积分10
21秒前
情怀的应助被科研通管家采纳,获得10
21秒前
沧海一兰完成签到,获得积分10
21秒前
张伟的应助被科研通管家采纳,获得10
21秒前
秋风的应助被科研通管家采纳,获得10
22秒前
22秒前
完美世界的应助被科研通管家采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191198
求助须知:如何正确求助?哪些是违规求助? 9578129
关于积分的说明 21856860
捐赠科研通 7790454
什么是DOI,文献DOI怎么找? 3436543
关于科研通互助平台的介绍 2560339
邀请新用户注册赠送积分活动 2483298